About CD2 antigen cytoplasmic tail-binding protein 2
CD2 antigen cytoplasmic tail-binding protein 2 (CD2BP2) is a protein
from Homo sapiens identified by UniProt accession
O95400, 341 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | CD2 antigen cytoplasmic tail-binding protein 2 |
|---|
| UniProt accession | O95400 |
|---|
| Gene | CD2BP2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 341 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (18)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- mean corpuscular volume · score 0.04
- platelet component distribution width · score 0.03
- red blood cell density measurement · score 0.02
- mean platelet volume · score 0.02
- systemic juvenile idiopathic arthritis · score 0.01
- Miyoshi myopathy · score 0.01
- myelodysplastic syndrome · score 0.01
- infection · score 0.00
- infect · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95400-F1 | alphafold | PREDICTED | 69.01 | — |
Amino-acid sequence (341 residues)
MPKRKVTFQG VGDEEDEDEI IVPKKKLVDP VAGSGGPGSR FKGKHSLDSD EEEDDDDGGS SKYDILASED VEGQEAATLP SEGGVRITPF NLQEEMEEGH FDADGNYFLN RDAQIRDSWL DNIDWVKIRE RPPGQRQASD SEEEDSLGQT SMSAQALLEG LLELLLPRET VAGALRRLGA RGGGKGRKGP GQPSSPQRLD RLSGLADQMV ARGNLGVYQE TRERLAMRLK GLGCQTLGPH NPTPPPSLDM FAEELAEEEL ETPTPTQRGE AESRGDGLVD VMWEYKWENT GDAELYGPFT SAQMQTWVSE GYFPDGVYCR KLDPPGGQFY NSKRIDFDLY T
Explore CD2 antigen cytoplasmic tail-binding protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets